Results 181 to 190 of about 44,923 (207)

Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05)

Annals of Oncology, 2015
Y Kakeji, M Kochi
exaly  

Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: A randomised phase III trial (TCOG GI-0801/BIRIP trial)

European Journal of Cancer, 2014
Toshikazu Moriwaki, Mizutomo Azuma, Katsuhiko Higuchi   +2 more
exaly  

Irinotecan

Reactions Weekly, 2003
openaire   +3 more sources

Prevention of irinotecan induced diarrhea by probiotics: A randomized double blind, placebo controlled pilot study

Complementary Therapies in Medicine, 2015
Michal Mego, Daniela Svetlovska, Vera Miškovská   +2 more
exaly  

Irinotecan-encapsulated double-reverse thermosensitive nanocarrier system for rectal administration

Drug Delivery, 2017
Dong Shik Kim, Ömer Mustapha, Dong Wuk Kim   +2 more
exaly  

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer

Lancet, The, 1998
Roberto Labianca, Christian Jacques, Matilde Navarro   +2 more
exaly  

Importance of UDP-glucuronosyltransferase 1A1∗6 for irinotecan toxicities in Japanese cancer patients

Cancer Letters, 2008
Kimie Sai, Yoshiro Saito, Nahoko Kaniwa   +2 more
exaly  

IRINOTECAN PREPARATION

2005
YOSHINO KEISUKE, NOZAWA SHIGENORI, ISOZAKI MASASHI, SAWADA SEIGO, KATO IKUO, MATSUZAKI TAKESHI   +5 more
openaire   +2 more sources

Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study

Annals of Oncology, 2004
Johannes Bukki, V Gorbunova, C Peschel   +2 more
exaly  

Irinotecan

Reactions Weekly, 2017
  +4 more sources